Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
16 avr. 2024 02h30 HE
|
Nxera Pharma
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine BiosciencesSuccessful completion of...
Anorexia Nervosa Treatment Advances with New 2024 Pipeline Landscape Report
27 févr. 2024 11h06 HE
|
Research and Markets
Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Anorexia Nervosa - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. A Comprehensive Overview of Emerging...
Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
04 janv. 2024 06h30 HE
|
Kynexis
KYN-5356 is an innovative, first-in-class small molecule that targets KAT-II, a key enzyme in the kynurenine pathwayTopline results are expected in the second half of 2024 NAARDEN, The Netherlands,...
Understanding Resilience to Schizophrenia through Genetics - A Free Webinar from the Brain & Behavior Research Foundation
05 déc. 2023 10h45 HE
|
Brain & Behavior Research Foundation
New York, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Understanding Resilience to Schizophrenia through Genetics” on Tuesday,...
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
07 nov. 2023 07h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases
07 nov. 2023 05h00 HE
|
Kynexis
- Lead Candidate KYN-5356, a First-In-Class Small Molecule KAT-II Inhibitor, Advancing Toward the Clinic for Cognitive Impairment Associated With Schizophrenia - €57 Million Series A Led by Forbion ...
Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration
31 oct. 2023 07h00 HE
|
Verge Genomics
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today...
Schizophrenia Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - Otsuka, Boehringer Ingelheim, Merck, Sunivion, PsychoGenics, Neurocrine Biosciences, Takeda, Lyndra, Cerevel
17 oct. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Schizophrenia Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - Otsuka, Boehringer Ingelheim,...
The Future of Global Mental Health Management Research Report 2023: Complementing Prescription Therapies with AI/ML/VR for Better Outcomes to Become More Prominent
20 juil. 2023 05h38 HE
|
Research and Markets
Dublin, July 20, 2023 (GLOBE NEWSWIRE) -- The "The Future of Mental Health Management" report has been added to ResearchAndMarkets.com's offering. This report identifies the challenges, drivers,...
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
28 juin 2023 08h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...